Skip to main content

Table 1 Baseline characteristics of patients according to treatment arm

From: The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive individuals

 

HIV-negative

HIV-positive

 

Arm A

No HAART

Arm B

NRTI-containing

Arm C1

NRTI-free

Arm C2

 

n = 50

n = 49

n = 49

n = 20

Age [years]**

41 (25 - 55)

39 (24 - 47)

42 (30 - 47)

43 (34 - 61)

Male sex* [%]

60

74

76

85

Transmission risk [%]

    

    IVDU

40

33

25

5

    Blood products

10

2

8

-

    Sexual

8

2

10

10

    other

8

2

-

-

    unknown/missing

34

61

57

85

HCV-genotype [%]

    1

52

51

51

50

    2

6

8

4

5

    3

38

27

31

40

    4

-

8

10

5

    other

4

4

2

-

    untypable

-

2

2

-

HCV-RNA [IU/ml, log 10 ]

5.7 (4.5 - 6.8)

5.7 (4.1 - 6.7)

5.5 (4.4 - 6.8)

5.9 (4.3 - 7.3)

≥ 500 000 IU/ml [%]

56

57

41

65

    ALT [IU/l]

61 (21 - 179)

68 (17 - 212)

71 (30 - 221)

75 (26 - 231)

HAART [%]

    PI/NNRTI/3 × NUC

-

-

57/29/12

95/5/0

    AZT

  

33

-

    d4T

  

18

-

    ABC

  

31

-

    3TC/FTC

  

98

-

    TDF

  

47

-

HIV-RNA [copies/ml, log 10 ]**

-

3.9 (1.9 - 4.9)

1.7 (1.7 - 3.5)

1.7 (1.7 - 4.5)

CD4-cellcount

    [/μl]**

-

580 (301 - 1042)

491 (222 - 781)

390 (152 - 846)

    [%]

-

27 (15 - 41)

27 (13 - 40)

22 (16 - 41)

  1. * Statistically significant difference comparing arm A with arms B and C (HIV-positive vs. HIV-negative)
  2. ** Statistically significant difference comparing arm B versus C1 versus C2
  3. Data shown as percent of patients or median (95% range). NRTI nucleos(t)ide reverse transcriptase inhibitor, IVDU intravenous drug abuse, other double infections, e.g. genotype 1 and 2 infection; PI protease inhibitor containing HAART, NNRTI non-nucleoside reverse transcriptase inhibitor containing HAART, 3xNUC HAART based on at least 3 nucleos(t)ides, AZT zidovudine, d4T stavudine, ABC abacavir, TDF tenofovir DF
Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us